<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240409001144&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240409001144&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 09 Apr 2024 04:11:47 +0000</lastbuilddate>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588337/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1169-1171. doi: 10.1161/CIRCULATIONAHA.124.067985. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588337/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588337</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067985>10.1161/CIRCULATIONAHA.124.067985</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588337</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:38588337</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067985</dc:identifier>
</item>
<item>
<title>Correction to: Telehealth: Lessons Learned From the Pandemic and Keys to Effective Research and Policy Design</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588336/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):e1108. doi: 10.1161/CIR.0000000000001246. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588336/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588336</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001246>10.1161/CIR.0000000000001246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588336</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Telehealth: Lessons Learned From the Pandemic and Keys to Effective Research and Policy Design</dc:title>
<dc:identifier>pmid:38588336</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001246</dc:identifier>
</item>
<item>
<title>Hemodynamic Forces and Atherosclerosis: HEG1 at the Center of the Jigsaw Puzzle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1202-1204. doi: 10.1161/CIRCULATIONAHA.124.067882. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588335</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067882>10.1161/CIRCULATIONAHA.124.067882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588335</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>M Luisa Iruela-Arispe</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Hemodynamic Forces and Atherosclerosis: HEG1 at the Center of the Jigsaw Puzzle</dc:title>
<dc:identifier>pmid:38588335</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067882</dc:identifier>
</item>
<item>
<title>Single-Cell Multimodal Profiling of Atherosclerosis Identifies CD200 as a Cell Surface Lineage Marker of Vascular Smooth Muscle Cells and Their Derived Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1231-1233. doi: 10.1161/CIRCULATIONAHA.123.067092. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588334</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067092>10.1161/CIRCULATIONAHA.123.067092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588334</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Bashore</dc:creator>
<dc:creator>Allen Chung</dc:creator>
<dc:creator>Chinyere Ibikunle</dc:creator>
<dc:creator>Hanying Yan</dc:creator>
<dc:creator>Chenyi Xue</dc:creator>
<dc:creator>Mingyao Li</dc:creator>
<dc:creator>Robert C Bauer</dc:creator>
<dc:creator>Muredach P Reilly</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Single-Cell Multimodal Profiling of Atherosclerosis Identifies CD200 as a Cell Surface Lineage Marker of Vascular Smooth Muscle Cells and Their Derived Cells</dc:title>
<dc:identifier>pmid:38588334</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067092</dc:identifier>
</item>
<item>
<title>Summarizing Primary Results in Clinical Trials With a Time-to-Event End Point: Complementing Different Measures for a Comprehensive Assessment of Treatment Effect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1154-1156. doi: 10.1161/CIRCULATIONAHA.123.068037. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588333</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068037>10.1161/CIRCULATIONAHA.123.068037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588333</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Summarizing Primary Results in Clinical Trials With a Time-to-Event End Point: Complementing Different Measures for a Comprehensive Assessment of Treatment Effect</dc:title>
<dc:identifier>pmid:38588333</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068037</dc:identifier>
</item>
<item>
<title>Peripheral Artery Disease: Past and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588332/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1151-1153. doi: 10.1161/CIRCULATIONAHA.123.065470. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588332/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38588332</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065470>10.1161/CIRCULATIONAHA.123.065470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588332</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mary M McDermott</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Peripheral Artery Disease: Past and Future</dc:title>
<dc:identifier>pmid:38588332</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065470</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):476-477. doi: 10.1161/RES.0000000000000665. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587929</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000665>10.1161/RES.0000000000000665</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587929</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38587929</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000665</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 2;134(3):246. doi: 10.1161/RES.0000000000000656. Epub 2024 Feb 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587928</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000656>10.1161/RES.0000000000000656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587928</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38587928</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000656</dc:identifier>
</item>
<item>
<title>Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):1. doi: 10.1161/RES.0000000000000652. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587925</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000652>10.1161/RES.0000000000000652</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587925</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38587925</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000652</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587923/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):3-5. doi: 10.1161/RES.0000000000000651. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587923/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587923</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000651>10.1161/RES.0000000000000651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587923</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38587923</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000651</dc:identifier>
</item>
<item>
<title>Circulation Research and 70 Years of Basic Science: Examining the Past and Looking Forward to the Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 5;134(1):6-8. doi: 10.1161/CIRCRESAHA.123.323177. Epub 2024 Jan 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587922</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323177>10.1161/CIRCRESAHA.123.323177</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587922</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jane E Freedman</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Circulation Research and 70 Years of Basic Science: Examining the Past and Looking Forward to the Future</dc:title>
<dc:identifier>pmid:38587922</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323177</dc:identifier>
</item>
<item>
<title>Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET BP I Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Alcohol-mediated RDN was associated with a modest but statistically significant reduction in 24-hour ambulatory systolic BP compared with sham control. No significant differences between groups in office BP or 6-month major adverse events were observed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 8. doi: 10.1161/CIRCULATIONAHA.124.069291. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN has not been formally studied in this indication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded trial investigating the safety and efficacy of alcohol-mediated RDN. Patients with office systolic blood pressure (SBP) ≥150 and ≤180 mmHg, office diastolic BP ≥90 mmHg and mean 24-hour ambulatory SBP ≥135 and ≤170 mmHg, despite prescription of 2-5 antihypertensive medications were enrolled. The primary endpoint was the baseline-adjusted change in mean 24-hour ambulatory systolic BP at 3 months post procedure. Secondary endpoints include mean between-group differences in office and ambulatory BP at additional time points.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 301 patients randomized 1:1 to RDN or sham control, RDN was associated with a significant reduction in 24-hour ambulatory SBP at 3 months (mean ± standard deviation -10.0 ± 14.2 mmHg versus -6.8 ± 12.1 mmHg, treatment difference -3.2 mmHg, 95% confidence interval [CI] -6.3, 0.0 mmHg; <i>P</i>=0.0487). Subgroup analysis of the primary endpoint revealed no significant interaction across predefined subgroups. At 3 months, the mean change in office SBP was -12.7 ± 18.3 mmHg and -9.7 ± 17.3 mmHg (difference, -3.0, 95% CI -7.0, 1.0; <i>P</i>=0.173), for RDN and sham, respectively. No significant differences in ambulatory or office diastolic BP were observed. Adverse safety events through 6 months were uncommon with 1 instance of accessory renal artery dissection in the RDN group (0.7%). No significant between-group differences in medication changes or patient adherence were identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Alcohol-mediated RDN was associated with a modest but statistically significant reduction in 24-hour ambulatory systolic BP compared with sham control. No significant differences between groups in office BP or 6-month major adverse events were observed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587557</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069291>10.1161/CIRCULATIONAHA.124.069291</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587557</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Michael A Weber</dc:creator>
<dc:creator>Atul Pathak</dc:creator>
<dc:creator>James P Zidar</dc:creator>
<dc:creator>Manish Saxena</dc:creator>
<dc:creator>Shukri W David</dc:creator>
<dc:creator>Roland E Schmieder</dc:creator>
<dc:creator>Adam J Janas</dc:creator>
<dc:creator>Christoph Langer</dc:creator>
<dc:creator>Alexandre Persu</dc:creator>
<dc:creator>Farrell O Mendelsohn</dc:creator>
<dc:creator>Koen Ameloot</dc:creator>
<dc:creator>Malcolm Foster Iii</dc:creator>
<dc:creator>Tim A Fischell</dc:creator>
<dc:creator>Helen Parise</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET BP I Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38587557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069291</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 16;134(4):344-345. doi: 10.1161/RES.0000000000000662. Epub 2024 Feb 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587409</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000662>10.1161/RES.0000000000000662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587409</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38587409</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000662</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):136-137. doi: 10.1161/RES.0000000000000654. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587404</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000654>10.1161/RES.0000000000000654</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587404</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38587404</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000654</dc:identifier>
</item>
<item>
<title>Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38587333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients having cardiac surgery, topical administration of tranexamic acid resulted in an 8.3% absolute increase in transfusion without reducing the incidence of seizure, compared to intravenous tranexamic acid.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 8. doi: 10.1161/CIRCULATIONAHA.124.069606. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although intravenous tranexamic acid is used in cardiac surgery to reduce bleeding and transfusion, topical tranexamic acid results in lower plasma concentrations compared to intravenous tranexamic acid, which may lower the risk of seizures. We aimed to determine whether topical tranexamic acid reduces the risk of in-hospital seizure without increasing the risk of transfusion among cardiac surgery patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a multicenter, double dummy, blinded, randomized controlled trial of patients recruited by convenience sampling in academic hospitals undergoing cardiac surgery with cardiopulmonary bypass. Between September 17, 2019, and November 28, 2023, a total of 3242 patients from 16 hospitals in 6 countries were randomly assigned (1:1 ratio) to receive either intravenous tranexamic acid (control) through surgery or topical tranexamic acid (treatment) at the end of surgery. The primary outcome was seizure, and the secondary outcome was red blood cell transfusion. After the last planned interim analysis-when 75% of anticipated participants had completed follow up-the Data and Safety Monitoring Board recommended to terminate the trial, and upon unblinding, the Operations Committee stopped the trial for safety.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3242 randomized patients (mean age, 66.0 years; 77.7% male), in-hospital seizure occurred in 4 of 1624 patients (0.2%) in the topical group and in 11 of 1628 patients (0.7%) in the intravenous group (absolute risk difference, -0.5%; 95% CI, -0.9 to 0.03; <i>P</i> = .07). Red blood cell transfusion occurred in 570 patients (35.1%) in the topical group and in 433 (26.8%) in the intravenous group (absolute risk difference, 8.3%; 95% CI, 5.2 to 11.5; <i>P</i> = .007). The absolute risk difference in transfusion of ≥4 units of red blood cells in the topical group compared to the intravenous group was 8.2% (95% CI, 3.4 to 12.9).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients having cardiac surgery, topical administration of tranexamic acid resulted in an 8.3% absolute increase in transfusion without reducing the incidence of seizure, compared to intravenous tranexamic acid.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38587333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38587333</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069606>10.1161/CIRCULATIONAHA.124.069606</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38587333</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>André Lamy</dc:creator>
<dc:creator>Dmitry A Sirota</dc:creator>
<dc:creator>Frederic Jacques</dc:creator>
<dc:creator>Ahmad Poostizadeh</dc:creator>
<dc:creator>Nicolas Noiseux</dc:creator>
<dc:creator>Sergey Efremov</dc:creator>
<dc:creator>Philippe Demers</dc:creator>
<dc:creator>Boris Akselrod</dc:creator>
<dc:creator>Chew Yin Wang</dc:creator>
<dc:creator>Rakesh C Arora</dc:creator>
<dc:creator>Piotr Branny</dc:creator>
<dc:creator>Shay P McGuinness</dc:creator>
<dc:creator>Craig D Brown</dc:creator>
<dc:creator>Hugues Jeanmart</dc:creator>
<dc:creator>Qiang Zhao</dc:creator>
<dc:creator>Haibo Zhang</dc:creator>
<dc:creator>Emilie P Belley-Côté</dc:creator>
<dc:creator>Richard P Whitlock</dc:creator>
<dc:creator>Austin Browne</dc:creator>
<dc:creator>Ingrid Copland</dc:creator>
<dc:creator>Jessica Vincent</dc:creator>
<dc:creator>Rutaba Khatun</dc:creator>
<dc:creator>Kumar Balasubramanian</dc:creator>
<dc:creator>Shrikant I Bangdiwala</dc:creator>
<dc:creator>Michael H McGillion</dc:creator>
<dc:creator>Alison E Fox-Robichaud</dc:creator>
<dc:creator>Jessica Spence</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>P J Devereaux</dc:creator>
<dc:creator>DEPOSITION Study Group</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:38587333</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069606</dc:identifier>
</item>
<item>
<title>Asparagine Synthetase Marks a Distinct Dependency Threshold for Cardiomyocyte Dedifferentiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38586957/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We discovered a novel gene Asns as both a molecular marker and an essential mediator, marking a distinct threshold that appears in common for at least 4 models of CMDD, and revealing an Asns/mammalian target of rapamycin complex 1 axis dependency for dedifferentiating cardiomyocytes. Further study will be needed to extrapolate and assess its relevance to other cell state transitions as well as in heart regeneration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 8. doi: 10.1161/CIRCULATIONAHA.123.063965. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Adult mammalian cardiomyocytes have limited proliferative capacity, but in specifically induced contexts they traverse through cell-cycle reentry, offering the potential for heart regeneration. Endogenous cardiomyocyte proliferation is preceded by cardiomyocyte dedifferentiation (CMDD), wherein adult cardiomyocytes revert to a less matured state that is distinct from the classical myocardial fetal stress gene response associated with heart failure. However, very little is known about CMDD as a defined cardiomyocyte cell state in transition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Here, we leveraged 2 models of in vitro cultured adult mouse cardiomyocytes and in vivo adeno-associated virus serotype 9 cardiomyocyte-targeted delivery of reprogramming factors (<i>Oct4</i>, <i>Sox2</i>, <i>Klf4</i>, and <i>Myc</i>) in adult mice to study CMDD. We profiled their transcriptomes using RNA sequencing, in combination with multiple published data sets, with the aim of identifying a common denominator for tracking CMDD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RNA sequencing and integrated analysis identified <i>Asparagine Synthetase</i> (<i>Asns</i>) as a unique molecular marker gene well correlated with CMDD, required for increased asparagine and also for distinct fluxes in other amino acids. Although <i>Asns</i> overexpression in <i>Oct4</i>, <i>Sox2</i>, <i>Klf4</i>, and <i>Myc</i> cardiomyocytes augmented hallmarks of CMDD, <i>Asns</i> deficiency led to defective regeneration in the neonatal mouse myocardial infarction model, increased cell death of cultured adult cardiomyocytes, and reduced cell cycle in <i>Oct4</i>, <i>Sox2</i>, <i>Klf4</i>, and <i>Myc</i> cardiomyocytes, at least in part through disrupting the mammalian target of rapamycin complex 1 pathway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We discovered a novel gene <i>Asns</i> as both a molecular marker and an essential mediator, marking a distinct threshold that appears in common for at least 4 models of CMDD, and revealing an <i>Asns</i>/mammalian target of rapamycin complex 1 axis dependency for dedifferentiating cardiomyocytes. Further study will be needed to extrapolate and assess its relevance to other cell state transitions as well as in heart regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38586957/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38586957</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063965>10.1161/CIRCULATIONAHA.123.063965</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38586957</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yike Zhu</dc:creator>
<dc:creator>Matthew Ackers-Johnson</dc:creator>
<dc:creator>Muthu K Shanmugam</dc:creator>
<dc:creator>Leroy Sivappiragasam Pakkiri</dc:creator>
<dc:creator>Chester Lee Drum</dc:creator>
<dc:creator>Yanpu Chen</dc:creator>
<dc:creator>Johnny Kim</dc:creator>
<dc:creator>Wyatt G Paltzer</dc:creator>
<dc:creator>Ahmed I Mahmoud</dc:creator>
<dc:creator>Wilson Lek Wen Tan</dc:creator>
<dc:creator>Mick Chang Jie Lee</dc:creator>
<dc:creator>Jianming Jiang</dc:creator>
<dc:creator>Danh Anh Tuan Luu</dc:creator>
<dc:creator>Shi Ling Ng</dc:creator>
<dc:creator>Peter Yi Qing Li</dc:creator>
<dc:creator>Anhui Wang</dc:creator>
<dc:creator>Rong Qi</dc:creator>
<dc:creator>Gabriel Jing Xiang Ong</dc:creator>
<dc:creator>Timothy Ng Yu</dc:creator>
<dc:creator>Jody J Haigh</dc:creator>
<dc:creator>Zenia Tiang</dc:creator>
<dc:creator>A Mark Richards</dc:creator>
<dc:creator>Roger Foo</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Asparagine Synthetase Marks a Distinct Dependency Threshold for Cardiomyocyte Dedifferentiation</dc:title>
<dc:identifier>pmid:38586957</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063965</dc:identifier>
</item>
<item>
<title>Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)00940-9. doi: 10.1016/j.jacc.2024.03.368. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38583160</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.368>10.1016/j.jacc.2024.03.368</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583160</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Abdul Mannan Khan Minhas</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Vijay Nambi</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Sankar D Navaneethan</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Dmitry Abramov</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States</dc:title>
<dc:identifier>pmid:38583160</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.368</dc:identifier>
</item>
<item>
<title>Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PRO-HF was an open-label, parallel, patient-level randomized clinical trial of routine PRO assessment or usual care at an academic HF clinic between August 30, 2021, and June 30, 2022, with 1 year of follow-up. In the PRO assessment arm, participants completed the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) at each HF clinic visit and results were shared with their treating clinician. The usual care arm completed the KCCQ-12 at randomization and 1 year later, which was not shared with the treating clinician. The primary outcome was the KCCQ-12 Overall Summary Score (OSS) between 12-15 months post-randomization. Secondary outcomes included domains of the KCCQ-12, hospitalization and emergency department visit rates, HF medication therapy, clinic visit frequency, and testing rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Across 17 clinicians, 1,248 participants were enrolled and randomized to PRO assessment (n=624) or usual care (n=624). The median age was 63.9 (interquartile range [IQR] 51.8-72.8), 38.9% were women, and the median baseline KCCQ-12 OSS was 82.3 (IQR 58.3-94.8). Final KCCQ-12 (available in 87.9% of the PRO arm and 85.1% in usual care [p=0.16]) median OSS scores were 87.5 (IQR 68.8-96.9) in the PRO arm and 87.6 (IQR 69.7-96.9) in the usual care arm with a baseline-adjusted mean difference of 0.2 (95% CI: -1.7 to 2.0; p=0.85). The results were consistent across pre-specified subgroups. A post hoc analysis demonstrated a significant interaction with greater benefit among participants with baseline KCCQ-12 OSS scores of 60-80 but not in less or more symptomatic participants. No significant differences were found in 1-year mortality, hospitalizations, ED visits, medication therapy, clinic follow-up, or testing rates between arms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38583147</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069624>10.1161/CIRCULATIONAHA.124.069624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583147</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Jamie Calma</dc:creator>
<dc:creator>Megan Skye</dc:creator>
<dc:creator>Neil M Kalwani</dc:creator>
<dc:creator>Jimmy Zheng</dc:creator>
<dc:creator>Jessica Schirmer</dc:creator>
<dc:creator>Natasha Din</dc:creator>
<dc:creator>Cati Brown Johnson</dc:creator>
<dc:creator>Anshal Gupta</dc:creator>
<dc:creator>Roy Lan</dc:creator>
<dc:creator>Brian Yu</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic</dc:title>
<dc:identifier>pmid:38583147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069624</dc:identifier>
</item>
<item>
<title>Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583146/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this randomized trial, a remote team-based program that identifies patients with T2D and high CV or kidney risk, provides virtual education, and prescribes SGLT2i or GLP-1 RA improves GDMT. These findings support greater utilization of virtual team-based approaches to optimize chronic disease management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Several sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular (CV) events and improve kidney outcomes in patients with type 2 diabetes (T2D); however, utilization remains low despite guideline recommendations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A randomized, remote implementation trial in the Mass General Brigham network enrolled patients with T2D at high CV and /or kidney risk. Patients eligible for, but not prescribed, SGLT2i or GLP-1 RA were randomly assigned to simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP-1 RA ("simultaneous") or two months of virtual education followed by medication prescription ("education-first") delivered by a multi-disciplinary team driven by non-licensed navigators and clinical pharmacists who prescribed SGLT2i or GLP-1 RA using a standardized treatment algorithm. The primary outcome was the proportion of patients with prescriptions for either SGLT2i or GLP-1 RA by 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between March 2021 and December 2022, 200 patients were randomized. Mean age was 66.5 years, 36.5% were female, 22.0% were non-White. Overall, 30.0% had cardiovascular CV disease, 5.0% had cerebrovascular disease, and 1.5% had both. Mean estimated glomerular filtration rate (eGFR) 77.9 mL/min/1.73m<sup>2</sup> and mean urine/albumin creatinine ratio (UACR) 88.6mg/g. After two months, 69/200 (34.5%) patients received a new prescription for either SGLT2i or GLP-1 RA: 53.4% of patients in the simultaneous arm vs. 8.3% of patients were in the education-first arm (p&lt;0.001). After six months, 128/200 (64.0%) received a new prescription: 69.8 % of patients in the simultaneous arm vs. 56.0% of patients in education-first (p&lt;0.001). Patient self-report of taking SGLT2i or GLP-1 RA within six months of trial entry was similarly higher in the simultaneous versus education-first arm (69 /116; 59.5% vs 37/84; 44.0%; p&lt;0.001) Median time to first prescription was 24 (IQR 13, 50) vs 85 days (IQR 65, 106), respectively (p&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this randomized trial, a remote team-based program that identifies patients with T2D and high CV or kidney risk, provides virtual education, and prescribes SGLT2i or GLP-1 RA improves GDMT. These findings support greater utilization of virtual team-based approaches to optimize chronic disease management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583146/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38583146</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069494>10.1161/CIRCULATIONAHA.124.069494</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583146</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander J Blood</dc:creator>
<dc:creator>Lee-Shing Chang</dc:creator>
<dc:creator>Shahzad Hassan</dc:creator>
<dc:creator>Jacqueline Chasse</dc:creator>
<dc:creator>Gretchen Stern</dc:creator>
<dc:creator>Daniel Gabovitch</dc:creator>
<dc:creator>David Zelle</dc:creator>
<dc:creator>Caitlin Colling</dc:creator>
<dc:creator>Samuel J Aronson</dc:creator>
<dc:creator>Christian Figueroa</dc:creator>
<dc:creator>Emma Collins</dc:creator>
<dc:creator>Ryan Ruggiero</dc:creator>
<dc:creator>Emily Zacherle</dc:creator>
<dc:creator>Josh Noone</dc:creator>
<dc:creator>Carey Robar</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Thomas A Gaziano</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Deborah J Wexler</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial</dc:title>
<dc:identifier>pmid:38583146</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069494</dc:identifier>
</item>
<item>
<title>Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of ASCVD, diabetes, kidney function or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of CV death, particularly HF and sudden cardiac death, without a significant effect on MI in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a collaborative trial-level meta-analysis from the SGLT2i meta-analysis cardio-renal trialists consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i across three patient populations (diabetes at high risk for atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], or chronic kidney disease [CKD]). The outcomes of interest were MACE (composite of CV death, myocardial infarction [MI], or stroke), individual components of MACE (inclusive of fatal and non-fatal events), all-cause mortality, and death subtypes. Effect estimates for SGLT2i vs. placebo were meta-analyzed across trials and examined across key subgroups (established ASCVD, prior MI, diabetes, prior HF, albuminuria, CKD stages and risk groups).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 78,607 patients across 11 trials were included: 42,568 (54.2%), 20,725 (26.4%), and 15,314 (19.5%) were included from trials of patients with diabetes at high risk for ASCVD, HF, or CKD, respectively. SGLT2i reduced the rate of MACE by 9% (HR 0.91 [95% CI 0.87-0.96], p&lt;0.0001) with a consistent effect across all three patient populations (<i>I</i><sup>2</sup>=0%) and across all key subgroups. This effect was primarily driven by a reduction in CV death (HR 0.86 [0.81-0.92], p&lt;0.0001), with no significant effect for MI in the overall population (HR 0.95 [0.87-1.04], p=0.29), and no effect on stroke (HR 0.99 [0.91-1.07], p=0.77). The benefit for CV death was driven primarily by reductions in HF death and sudden cardiac death (HR 0.68 [0.46-1.02] and HR 0.86 [0.78-0.95], respectively) and was generally consistent across subgroups, with the possible exception of being more apparent in those with albuminuria (P<sub>int</sub>=0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of ASCVD, diabetes, kidney function or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of CV death, particularly HF and sudden cardiac death, without a significant effect on MI in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38583093</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069568>10.1161/CIRCULATIONAHA.124.069568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583093</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Yu Mi Kang</dc:creator>
<dc:creator>KyungAh Im</dc:creator>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>David Z I Cherney</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Robert A Fletcher</dc:creator>
<dc:creator>William G Herrington</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Meg J Jardine</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Natalie Staplin</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>David C Wheeler</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Yujie Zhao</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Stephen D Wiviott</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis</dc:title>
<dc:identifier>pmid:38583093</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069568</dc:identifier>
</item>
<item>
<title>Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409001144&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg/dL threshold of acute pancreatitis risk in most participants. Other triglyceride-related lipoprotein parameters improved. An increase in LDL-C level was observed but with no change in ApoB level and a decrease in non-HDL-C level. The safety profile was generally favorable at all doses. Additional studies will be required to determine whether...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 7. doi: 10.1001/jamacardio.2024.0959. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis. Despite available treatments, persistent ASCVD and acute pancreatitis-associated morbidity from sHTG remains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering-RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in patients with sHTG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2) was a placebo-controlled, double-blind, dose-ranging, phase 2b randomized clinical trial enrolling adults with sHTG at 74 centers across the US, Europe, New Zealand, Australia, and Canada from May 31, 2021, to August 31, 2023. Eligible patients had fasting triglyceride levels in the range of 500 to 4000 mg/dL (to convert to millimoles per liter, multiply by 0.0113) while receiving stable lipid-lowering treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants received 2 subcutaneous doses of plozasiran (10, 25, or 50 mg) or matched placebo on day 1 and at week 12 and were followed up through week 48.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point evaluated the placebo-subtracted difference in means of percentage triglyceride change at week 24. Mixed-model repeated measures were used for statistical modeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 229 patients, 226 (mean [SD] age, 55 [11] years; 176 male [78%]) were included in the primary analysis. Baseline mean (SD) triglyceride level was 897 (625) mg/dL and plasma APOC3 level was 32 (16) mg/dL. Plozasiran induced significant dose-dependent placebo-adjusted least squares (LS)-mean reductions in triglyceride levels (primary end point) of -57% (95% CI, -71.9% to -42.1%; P &lt; .001), driven by placebo-adjusted reductions in APOC3 of -77% (95% CI, -89.1% to -65.8%; P &lt; .001) at week 24 with the highest dose. Among plozasiran-treated patients, 144 of 159 (90.6%) achieved a triglyceride level of less than 500 mg/dL. Plozasiran was associated with dose-dependent increases in low-density lipoprotein cholesterol (LDL-C) level, which was significant in patients receiving the highest dose (placebo-adjusted LS-mean increase 60% (95% CI, 31%-89%; P &lt; .001). However, apolipoprotein B (ApoB) levels did not increase, and non-high-density lipoprotein cholesterol (HDL-C) levels decreased significantly at all doses, with a placebo-adjusted change of -20% at the highest dose. There were also significant durable reductions in remnant cholesterol and ApoB48 as well as increases in HDL-C level through week 48. Adverse event rates were similar in plozasiran-treated patients vs placebo. Serious adverse events were mild to moderate, not considered treatment related, and none led to discontinuation or death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg/dL threshold of acute pancreatitis risk in most participants. Other triglyceride-related lipoprotein parameters improved. An increase in LDL-C level was observed but with no change in ApoB level and a decrease in non-HDL-C level. The safety profile was generally favorable at all doses. Additional studies will be required to determine whether plozasiran favorably modulates the risk of sHTG-associated complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04720534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409001144&v=2.18.0.post9+e462414">38583092</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0959>10.1001/jamacardio.2024.0959</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583092</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Denes Pall</dc:creator>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Karen Modesto</dc:creator>
<dc:creator>Javier San Martin</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38583092</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0959</dc:identifier>
</item>





























</channel>
</rss>